Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · June 06, 2022

Adjuvant Abemaciclib Added to Endocrine Therapy for High-Risk Early Breast Cancer

Annals of Oncology

 

Additional Info

Annals of Oncology
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
Ann. Oncol 2022 Jun 01;33(6)616-627, HS Rugo, J O'Shaughnessy, F Boyle, M Toi, R Broom, I Blancas, M Gumus, T Yamashita, YH Im, P Rastogi, F Zagouri, C Song, M Campone, B San Antonio, A Shahir, M Hulstijn, J Brown, A Zimmermann, R Wei, SRD Johnston, M Reinisch, SM Tolaney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading